British scientists have identified a gene responsible for angiogenesis – suggesting the possibility of treatments to stimulate blood vessel growth, it was announced today.
Turning off the Wars2 gene reduces blood vessel growth in the heart and throughout the rest of the body, in tests on rats and zebrafish, found an international team.
Dr Rizwan Ahmed of Royal Brompton & Harefield NHS Foundation Trust, UK, and colleagues explain that coronary flow is largely determined by capillary density, which in turn reflects blood vessel formation in the heart.
They investigated this process and found that coronary flow in rats is influenced by an area on rat chromosome 2, which is also linked to capillary density in the heart.
The Wars2 gene, overseeing a type of L53F protein, was identified as controlling this process by analysing several genome databases. Inhibition of Wars2 reduced angiogenesis in zebrafish and rats, causing impaired heart function.
"Our data demonstrate a pro-angiogenic function for Wars2 both within and outside the heart that may have translational relevance given the association of Wars2 with common human diseases," the team writes today (20th July) in Nature Communications.
They believe the findings could also lead to new treatments for other common diseases besides heart disease. This gene has previously been linked to obesity and cancer in large genetic studies, they add.
Dr Ahmed commented: "We are now one step closer to improving heart function in people with an obstructed or reduced blood flow to the heart muscle. Our findings could lead to new treatments to stimulate blood vessel production in the heart.
"The next step is to find medications to activate blood vessel production specifically in the heart muscle, using this gene. This research was an important step forward to help us target a gene known to be important in a range of conditions."
Professor Jeremy Pearson, of the British Heart Foundation, which helped fund the research, said: “This careful genetic study has found a new gene that controls cardiac blood vessel growth, opening up the potential for new therapies to enhance blood supply to the failing heart.
“This new insight into the role of Wars2 in blood vessel growth will allow researchers around the world to explore a fresh new target to treat diseases which are characterised by impaired blood vessel formation.”
Wang, M. et al. Wars2 is a determinant of angiogenesis. Nature Communications 20 July 2016 doi: 10.1038/ncomms12061 [abstract]

Leave a Reply